AnaptysBio (ANAB) has drawn renewed attention after recent trading left the stock at a last close of $57.61. The company’s clinical-stage immunology portfolio and collaborations are in focus for investors.

Recent trading has been choppy for AnaptysBio, with the share price slipping 3.19% over the last day and also down over the past month and quarter, yet supported by a 28.16% year to date share price return and a very large 1 year total shareholder return of 262.84% that signals strong momentum over a longer horizon.

If you are widening your search in healthcare and biotech, this is a good moment to review other potential opportunities through our screener of 40 healthcare AI stocks.

With AnaptysBio shares sitting at $57.61, a value score of 4, an intrinsic discount of 83.80% and a roughly 51% gap to the average analyst target price, you have to ask: is this genuine mispricing, or is the market already baking in future growth?

Preferred Price-to-Sales Multiple of 7.2x: Is It Justified?

At a last close of $57.61, AnaptysBio stock has a P/S ratio of 7.2x, which our data classifies as good value relative to both its biotech peers and the wider US Biotechs industry.

The P/S ratio compares the company’s market value to its revenue, which is particularly useful for clinical-stage biotechs like AnaptysBio that are not yet profitable. In this case, investors are effectively paying 7.2 times the company’s reported revenue of $232.39 million. This level reflects expectations around its immunology pipeline, collaborations with partners such as GSK and Vanda, and forecasts for earnings to grow 48.14% per year.

What stands out is how this multiple compares. AnaptysBio’s 7.2x P/S is described as good value next to the US Biotechs industry average of 10.5x and a peer group average of 27.3x. This implies the market is pricing the company at a discount to comparable stocks. However, when compared to an estimated fair P/S ratio of 4.5x, the shares are described as expensive on this specific measure. This suggests the multiple could move closer to that level if sentiment or expectations change.

Result: Price-to-sales ratio of 7.2x (UNDERVALUED)

However, there are clear risks to keep in mind, including AnaptysBio’s loss of $26.79 million and the clinical uncertainty across its early and mid stage pipeline.

Another View: What Does The SWS DCF Model Say About AnaptysBio?

There is a very different message when you look at AnaptysBio using the SWS DCF model instead of sales multiples. At a share price of $57.61 versus an estimated future cash flow value of $355.64, the stock screens as heavily undervalued. So which signal should carry more weight for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AnaptysBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around AnaptysBio can feel confusing, so consider your options while the stock is in focus and weigh both sides by checking the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond AnaptysBio?

If AnaptysBio has sharpened your interest in healthcare and growth stories, use this moment to line up your next moves with a few focused stock ideas.

• Tap into potential bargains by reviewing companies that appear mispriced on quality and valuation through our list of 44 high quality undervalued stocks.
• Strengthen your income stream by scanning for companies offering robust yields and consistent payouts with the support of our carefully curated 9 dividend fortresses.
• Prioritize resilience by checking companies that pair financial stability with lower risk scores using our targeted 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.